TERN — Terns Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $294.81m
- $31.37m
- 34
- 31
- 25
- 20
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 1 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 70.2 | 37 | 50.9 | 62 | 103 |
Operating Profit | -70.2 | -37 | -49.9 | -62 | -103 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -68.8 | -39.8 | -49.6 | -60 | -90 |
Provision for Income Taxes | |||||
Net Income After Taxes | -68.8 | -40.6 | -50.2 | -60.3 | -90.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -68.6 | -40.1 | -50.2 | -60.3 | -90.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -68.6 | -29.4 | -50.2 | -60.3 | -90.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.02 | -1.29 | -2.21 | -1.67 | -1.27 |
Dividends per Share |